Evidence map›Paper›PMID 42323468›Full record

ArticleCommunications biology2026

Oligodendrocyte Piezo2 is a regulator of age-dependent myelin integrity and dysregulated in multiple sclerosis.

Julia Dyckow-Schubart, Amelie M Rabitsch, Celine Geywitz, Christina Mayer, Celia Lerma-Martin, Natalie Ludwig, Matthew Smith, Heidrun Potschka, Peter A Calabresi, Klaus-Armin Nave and 3 more

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Julia Dyckow-SchubartDivision of Neuroimmunology, Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID 0000-0003-1423-9322
Amelie M RabitschDivision of Neuroimmunology, Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID 0009-0005-9624-6615
Celine GeywitzDivision of Neuroimmunology, Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID 0009-0008-1222-2627
Christina MayerInstitute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.ORCID 0000-0002-4148-2822
Celia Lerma-MartinDivision of Neuroimmunology, Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Natalie LudwigDivision of Neuroimmunology, Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.ORCID 0009-0003-9605-9989
Matthew SmithDepartments of Neurology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-6614-569X
Heidrun PotschkaInstitute of Pharmacology, Toxicology and Pharmacy, Ludwig-Maximilians-Universität, Munich, Germany.ORCID 0000-0003-1506-0252
Peter A CalabresiDepartments of Neurology and Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-7776-6472
Klaus-Armin NaveDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.ORCID 0000-0001-8724-9666
Manuel A FrieseInstitute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.ORCID 0000-0001-6380-2420
Wiebke MöbiusDepartment of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.ORCID 0000-0002-2902-7165
Lucas SchirmerDivision of Neuroimmunology, Department of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. lucas.schirmer@medma.uni-heidelberg.de.ORCID 0000-0001-7142-4116

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) SCHI 1330/10-1,SCHI 1330/11-1, SCHI 1330/13-1EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) P1180016National Multiple Sclerosis Society (National MS Society) RFA-2203-39300
6 · The paper itself

Abstract

Studies on the mechanosensitive ion channel Piezo2 largely focus on its role in the peripheral nervous system, particularly in touch and pain sensation. Here, we investigate Piezo2 function in the anterior visual pathway of the central nervous system with a focus on oligodendrocyte (OL) biology and myelin integrity. Using single-nucleus RNA sequencing, we identify Piezo2 expression in late differentiated OLs of the murine optic nerve, with minor expression in retinal ganglion cells. OL-specific Piezo2 deficiency results in age-dependent motor impairment and selective disruption of myelin compaction in small-caliber optic nerve axons, a fiber population known to be particularly vulnerable in demyelinating disease. Differential gene expression analysis further indicates that Piezo2 regulates myelin compaction and white matter integrity in mature OLs. Consistent with these findings, OL-encoded PIEZO2 expression is reduced in optic nerve lesion areas from multiple sclerosis patients, highlighting a convergent mechanism of small-caliber fiber vulnerability. Together, these data identify Piezo2 as an age-related regulator of OL function and myelin integrity, with potential relevance for preserving white matter structure in multiple sclerosis.

Indexed as

AgingIon ChannelsMultiple SclerosisMyelin SheathOligodendrogliaAge FactorsAnimalsFemaleHumansMiceOptic NerveIon ChannelsPIEZO2 protein, humanPiezo2 protein, mouse

Identifiers

PMID42323468
PMCPMC13283217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.